A 55-year-old male lung cancer patient with cT3N1M1a, Stage IVA, EGFR (−), ROS1 (+) adenocarcinoma presented with a pleural effusion and was treated with crizotinib 250 mg twice daily and referred to our department. Here, EGFR is linked to adenocarcinoma.